The field of drug discovery has long been challenged by the concept of "undruggable" targets—proteins and pathways that are crucial in disease processes but difficult to target with traditional small molecule drugs. One particularly challenging target is β-catenin, a key player in the Wnt/β-catenin
The healthcare industry is witnessing an unprecedented advancement with the introduction of AI-powered wearable cameras designed to detect and prevent medication errors. These errors are a significant concern, contributing to a substantial number of preventable harms, with medication errors alone
Imagine a world where cancer patients could receive personalized treatment precisely tailored to their unique biological makeup, drastically improving their chances of success. This once-idealistic vision is now becoming a reality with the advent of SCORPIO, an innovative AI-driven tool developed
Autoimmune diseases occur when the immune system erroneously targets the body's own cells and tissues. These diseases usually present a preclinical stage with mild symptoms or specific antibodies detectable in blood tests before the disease fully manifests. However, in some cases, these symptoms
Insilico Medicine, a clinical-stage company leveraging generative artificial intelligence (AI) for drug discovery and development, has announced promising results for its novel drug, ISM5411, aimed at treating Inflammatory Bowel Disease (IBD). This gut-restricted and PHD-specific inhibitor was
Artificial Intelligence (AI) is making significant strides in various fields, and drug development is no exception. While AI's applications in text generation, facial recognition, and autonomous driving are well-known, its potential in drug discovery is equally transformative, promising to save
